NCT06648733

Brief Summary

The transition of palliative care patients from inpatient to outpatient care is aimed to be improved through structured pharmaceutical discharge management by a trained pharmacist. This data will be compared with retrospective cases.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P50-P75 for not_applicable cancer

Timeline
Completed

Started Jun 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 20, 2024

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

June 27, 2024

Completed
4 months until next milestone

First Posted

Study publicly available on registry

October 18, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

June 13, 2025

Status Verified

October 1, 2024

Enrollment Period

1 year

First QC Date

June 27, 2024

Last Update Submit

June 10, 2025

Conditions

Keywords

Palliative Care

Outcome Measures

Primary Outcomes (2)

  • (I) Drug-related problems

    (I) Number of drug-related problems at the time of discharge according to PCNE (comparison of prospective, actually proposed changes vs. hypothetical number and type of problems at the time of discharge in the retrospective comparison cohort)

    12 months

  • (II) Drug-related problems

    (II) Type of drug-related problems at the time of discharge according to PCNE (comparison of prospective, actually proposed changes vs. hypothetical number and type of problems at the time of discharge in the retrospective comparison cohort)

    12 months

Secondary Outcomes (15)

  • Number of contacts

    12 months

  • Number of readmissions / visits

    12 months

  • Symptom burden

    12 months

  • (I) Medication changes

    12 months

  • Adoption rate

    12 months

  • +10 more secondary outcomes

Study Arms (2)

Prospective patients

EXPERIMENTAL

Current palliative care patients who are discharged from the University Hospital to outpatient palliative care.

Other: Structured pharmaceutical discharge management

Retrospective patients

NO INTERVENTION

Former palliative care patients who were discharged from the university hospital to outpatient palliative care.

Interventions

These patients will receive structured pharmaceutical discharge management from inpatient to outpatient care.

Prospective patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All individual indications for general and specialised palliative care as part of routine clinical practice (e.g.):
  • advanced, malignant tumour disease
  • advanced, chronic obstructive pulmonary disease
  • Patients with advanced disease and limited life expectancy (approx. 12 months) Further care in the SOPC Muenster (prospective data) Sufficient understanding of the German language to be able to understand the information and consent form

You may not qualify if:

  • Impossibility of understanding the information and declaration of consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Muenster

Münster, North Rhine-Westphalia, 48149, Germany

RECRUITING

MeSH Terms

Conditions

NeoplasmsHeart FailurePulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Christoph Klaas, Dr. rer. nat.

    Pharmacy of the University Hospital Muenster

    STUDY CHAIR

Central Study Contacts

Christoph Klaas, Dr. rer. nat.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 27, 2024

First Posted

October 18, 2024

Study Start

June 20, 2024

Primary Completion

June 30, 2025

Study Completion

December 31, 2025

Last Updated

June 13, 2025

Record last verified: 2024-10

Locations